Taro Pharmaceuticals Recalls Lamotrigine Tablets Due to Cross Contamination

Taro Pharmaceuticals Recalls Lamotrigine Tablets Due to Cross Contamination

Taro Pharmaceuticals has issued a recall notice for one lot of lamotrigine 100 mg tablets, as this lot was found to have been cross-contaminated with a small amount of Enalapril Maleate, a drug indicated for hypertension and congestive heart failure.

Lamotrigine tablets are indicated for epilepsy and bipolar disorder. Epilepsy and other seizure disorders may be present in workers’ comp claims.

The impacted lot, #331771 contains 100-count bottles and was distributed to wholesalers between August 23 and August 30, 2019, who may have further distributed the drugs. Chronic exposure to Enlapril Maleate can impact small children or pregnant women, and is associated with risk of birth defects in a developing fetus.

For further information, read the FDA’s recall notice.